<DOC>
	<DOC>NCT00772564</DOC>
	<brief_summary>The administration of high dose HMG-CoA reductase inhibitors (Statins) to patients with acute ST-elevation MI (hypoxia/ischemia) who are treated with primary PCI (reoxygenation/ reperfusion) will protect their cardiomyocytes from death and thus preserve LV ejection fraction.</brief_summary>
	<brief_title>The Use of Statins for Myocardial Death Prevention</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>1. Patients suffering from acute ST elevation resulting from myocardial infarction, Killip Classification 1 and 2 will be included atrandom to either group. Included subjects should be able to give their informed consent to participate in this study. 1. The impossibility to give the required informed consent. 2. Known allergy to Atorvastatin. 3. Base line serum creatinine of 1.4 mg/dL. 4. Killip Classification 3 and 4. 5. Persisting vomiting. 6. History of previous liver disease. 7. History of previous muscle disease or rabdomyolisis. 8. Treated already with high dose atorvastatin 9. Non Compliance.</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Acute ST Elevation Myocardial Infarction</keyword>
</DOC>